Newsroom

Nov 03, 2022

Orca Bio to Present Four Abstracts at the 64th American Society of Hematology Annual Meeting, Including Updated Relapse-Free Survival Data with Orca-T and the First Clinical Data for Orca-Q

View

Sep 08, 2022

Orca Bio Expands Manufacturing Capabilities to Develop and Commercialize its Precision Cell Therapies

View

Aug 02, 2022

Orca Bio Announces the Precision-T Phase 3 Study is Open and Enrolling Patients at Transplant Centers Across the U.S.

View

May 12, 2022

Orca Bio to Present New Clinical Data on Orca-T at the European Hematology Association 2022 Congress

View

Apr 25, 2022

Orca Bio Presents Positive Data Reinforcing Clinical Profile and Manufacturing Reliability of Orca-T at 2022 Transplantation & Cellular Therapy ASTCT and CIBMTR Tandem Meetings

View

Jan 06, 2022

Orca Bio to Present at the 40th Annual J.P. Morgan Healthcare Conference

View

Dec 11, 2021

Positive Clinical Results from More than 100 Patients Treated with Orca Bio’s Lead Investigational High Precision Cell Therapy Presented at 63rd ASH Annual Meeting

View

Nov 04, 2021

Orca Bio to Present New Clinical Data on Orca-T at the 63rd American Society of Hematology Annual Meeting

View